SCHEDULE 13G: Morgan Stanley Discloses 6.3% Stake in Syndax Pharmaceuticals

Morgan Stanley and its subsidiary, Morgan Stanley & Co. LLC, have disclosed beneficial ownership of 6.3% of Syndax Pharmaceuticals Inc.'s common stock as of December 31, 2024.

Summary

• Morgan Stanley, as a parent holding company, reported beneficial ownership of 5,362,169 shares of Syndax Pharmaceuticals Inc. common stock, representing 6.3% of the class.
• Morgan Stanley & Co. LLC, a wholly-owned subsidiary of Morgan Stanley, reported beneficial ownership of 5,055,451 shares, representing 5.9% of the class.
• The shares held by Morgan Stanley & Co. LLC are deemed to be beneficially owned by Morgan Stanley.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Syndax Pharmaceuticals Inc.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership, which is neutral in sentiment. It does not contain positive or negative performance indicators or forward-looking statements.

Future Outlook

NA

Industry Context

This filing is a routine disclosure of significant institutional ownership in a publicly traded company within the pharmaceutical sector. It reflects a passive investment by Morgan Stanley, indicating their position as a substantial shareholder in Syndax Pharmaceuticals Inc. without intent to influence control.

Stakeholder Impact

• Shareholders: The disclosure provides transparency regarding a significant institutional holder's stake, which can influence market perception and liquidity.

Key Dates

Keywords

Morgan Stanley, Syndax Pharmaceuticals, Beneficial Ownership, Schedule 13G, Common Stock, Institutional Ownership, SEC Filing